They are not drugs, foods, cosmetics, or dietary supplements, and are not for human or veterinary consumption, ingestion, injection, or any in-vivo diagnostic or therapeutic use
Recent efforts by Wegovy and Zepbound to pick up new indications to improve payer access have generally been a successful strategy but come with caveats at the payer level
PMID: 34982483 Invest New DrugsIMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis
Despite these trends, access remains a major barrier, particularly for low-income individuals who are uninsured or underinsured, highlighting the need to bridge the gap of affordability in the future
Medical history: Relevant history related to metabolic health, insulin resistance, or other conditions that might make GLP-1 therapy appropriate
If fasting guidelines are instead meant to minimize aspiration events without respect to residual gastric contents, then I think we need to start questioning what amount of residual gastric contents (and what type) are clinically significant.2 Oprea and colleagues published a correspondence this month addressing some of the criticisms of their article